Rep. April McClain Delaney Purchases Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Representative April McClain Delaney (D-Maryland) recently bought shares of IDEXX Laboratories, Inc. NASDAQ: IDXX. In a filing disclosed on April 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in IDEXX Laboratories stock on March 14th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Westinghouse Air Brake Technologies NYSE: WAB on 3/25/2025.
• Sold $1,001 - $15,000 in shares of Toro NYSE: TTC on 3/20/2025.
• Sold $15,001 - $50,000 in shares of Dayforce NYSE: DAY on 3/18/2025.
• Purchased $1,001 - $15,000 in shares of BJ's Wholesale Club NYSE: BJ on 3/17/2025.
• Purchased $1,001 - $15,000 in shares of Jones Lang LaSalle NYSE: JLL on 3/14/2025.
• Purchased $1,001 - $15,000 in shares of BJ's Wholesale Club NYSE: BJ on 3/14/2025.
• Purchased $1,001 - $15,000 in shares of Corpay NYSE: CPAY on 3/13/2025.
• Purchased $1,001 - $15,000 in shares of Jones Lang LaSalle NYSE: JLL on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 3/10/2025.
• Purchased $15,001 - $50,000 in shares of Markel Group NYSE: MKL on 3/7/2025.

IDEXX Laboratories Trading Down 3.6 %

Shares of IDXX stock opened at $410.76 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The firm's 50 day moving average price is $436.39 and its two-hundred day moving average price is $441.13. The stock has a market cap of $33.30 billion, a price-to-earnings ratio of 38.50, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IDXX. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, Bank of America boosted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $533.75.

Remove Ads

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the third quarter worth about $25,000. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $30,000. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $31,000. Finally, Colonial Trust Co SC raised its position in shares of IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after acquiring an additional 39 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.